GATEWAY PHARMACEUTICAL, LLC

Medtech · Still private

Colon-targeting, rapid-release metronidazole formulation (mini-tablets with specialized coating) for Clostridium difficile infection treatment

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$292K
Federal grants
$292K
1 award · 2018
Rank in peer group#9 of 23
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
3 pending · first 2020
Rank in peer group#5 of 23

Capital timeline

2018FEDERAL ↑EQUITY ↓Cumulative $292K$292K
2018FEDERAL ↑EQUITY ↓Cumulative $292K$292K

Latest events

  • Federal grantHealth and Human S · Phase I · Development of a new colon-targeting and rapid-release metronidazole treatment for Clostridium difficile infection$292K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 23 peers

Line = median

Medtech · Molecule

  • Federal grants#9 · top 39%
  • Granted patents#5 · top 22%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 4
  • GrantedPharmaceutical Compositions For Colon-specific DeliveryUSPTOUS 10,588,864
  • PendingPharmaceutical Compositions for Colon-Specific DeliveryUSPTOApplication 15379371
  • PendingPharmaceutical Compositions For Colon-specific DeliveryUSPTOApplication PCTUS2017021492
Show all 4 patent records
  • Pharmaceutical Compositions For Colon-specific DeliveryMar 17, 2020 · US 10,588,864Granted
  • Pharmaceutical Compositions for Colon-Specific DeliverySep 14, 2017 · Application 15379371Pending
  • Pharmaceutical Compositions For Colon-specific DeliveryApplication PCTUS2017021492Pending
  • Pharmaceutical Compositions for Colon-Specific DeliveryApplication 62307407Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .